US FDA approves Cytokinetics’ heart disease drug
The U.S. Food and Drug Administration has approved Cytokinetics’ drug to treat a rare heart condition, the company said on Friday.
The keenly watched drug, branded as Myqorzo, was approved for patients with obstructive hypertrophic cardiomyopathy, a condition in which the heart muscle becomes abnormally thick, limiting the heart’s pumping and causing symptoms such as shortness of breath, chest pain and dizziness.
The company said Myqorzo is expected to be available in the U.S. in the second half of January.
